Allogeneic marrow transplantation for acute nonlymphoblastic leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Bone marrow transplantation (BMT) is a potential cure for end-stage refractory acute leukemia, but historically faced challenges.
• Complications include graft-versus-host disease, interstitial pneumonitis, veno-occlusive disease, infections, and leukemia relapse.
• Early BMT in complete remission (CR) has improved outcomes, but age remains a significant factor.

Purpose of the Study:

• To evaluate the efficacy and long-term survival of BMT versus chemotherapy in acute nonlymphoblastic leukemia (ANL) patients in first CR.
• To determine optimal timing for BMT based on patient age.

Main Methods:

• Prospective comparative trial comparing BMT with chemotherapy for ANL in first CR.
• Analysis of early mortality, leukemia relapse rates, and long-term tumor-free survival.
• Stratification of results by patient age (e.g., <30 vs. >30 years).

Main Results:

• BMT demonstrated a higher early fatality rate within 6 months post-induction compared to chemotherapy.
• However, BMT significantly increased the probability of long-term tumor-free survival beyond the initial 6-month period.
• Post-BMT leukemia relapse rates decreased from 65% to 20-40% when performed in first CR, with overall long-term survival around 50%.

Conclusions:

• For ANL patients under 30 in first CR, BMT is recommended.
• For ANL patients over 30 in first CR, delaying BMT until the earliest sign of relapse is advised.
• BMT, despite initial risks, offers superior long-term leukemia control and survival compared to chemotherapy in select patient populations.